Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.

PURPOSE To prospectively and intraindividually compare equivalent (0.1 mmol per kilogram of body weight) doses of gadobenate dimeglumine and gadopentetate dimeglumine for accuracy of detection and characterization of breast lesions at contrast material-enhanced magnetic resonance (MR) mammography. MATERIALS AND METHODS Ethics committee approval and informed consent were obtained. Twenty-six consecutive women (mean age, 47.8 years) suspected of having a breast tumor at mammography and sonography underwent two identical MR examinations at 1.5 T; examinations were separated by more than 48 hours but less than 72 hours. A T1-weighted three-dimensional gradient-echo sequence was used, and images were acquired before and at 0, 2, 4, 6, and 8 minutes after randomized injection of gadopentetate dimeglumine or gadobenate dimeglumine at an identical flow rate of 2 mL/sec. Separate and combined assessment of unenhanced, contrast-enhanced, and subtracted images was performed blindly by two readers in consensus. Accuracy for lesion detection was determined against a final diagnosis based on findings at conventional mammography, sonography, and surgery. Sensitivity, specificity, positive and negative predictive values, and overall accuracy for malignant lesion identification were determined against histologic results. Data were analyzed with the McNemar test, proportional odds models, and analysis of variance. RESULTS MR mammography with gadobenate dimeglumine depicted significantly (P = .003) more lesions (45 of 46) than did that with gadopentetate dimeglumine (36 of 46), and detected lesions were significantly (P < .001) more conspicuous with gadobenate dimeglumine. Confidence for characterization was significantly (P = .031) greater with gadobenate dimeglumine. Comparison of the contrast agents for their ability to help identify malignant lesions revealed significant (P = .02) superiority for gadobenate dimeglumine: Sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy for malignant lesion identification were, respectively, 94.7%, 100%, 100%, 80.0%, and 95.6% with gadobenate dimeglumine and 76.3%, 100%, 100%, 47.1%, and 80.4% with gadopentetate dimeglumine. Quantitative evaluation of signal intensity-time curves revealed significantly (P < .001) greater lesion enhancement with gadobenate dimeglumine. CONCLUSION Detection of breast lesions and accurate identification of malignant lesions at MR imaging are significantly superior with gadobenate dimeglumine in comparison with gadopentetate dimeglumine.

[1]  E. Rummeny,et al.  Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver: An Intra-Individual Crossover Comparison , 2003, Investigative radiology.

[2]  C K Kuhl,et al.  Dynamic image interpretation of MRI of the breast , 2000, Journal of magnetic resonance imaging : JMRI.

[3]  M D Schnall,et al.  MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. , 2001, Radiology.

[4]  M D Schnall,et al.  Update of breast MR imaging architectural interpretation model. , 2001, Radiology.

[5]  L J van Erning,et al.  MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. , 1994, Radiology.

[6]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[7]  E. Mendelson.  Evaluation of the postoperative breast. , 1992, Radiologic clinics of North America.

[8]  M. Oudkerk,et al.  Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. , 2003, AJR. American journal of roentgenology.

[9]  M. Völk,et al.  Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. , 2001, Radiology.

[10]  Martin Requardt,et al.  Contrast‐enhanced MR angiography of the run‐off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine , 2003, Journal of magnetic resonance imaging : JMRI.

[11]  A. Padhani.  Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[12]  E A Sickles,et al.  Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. , 2000, AJR. American journal of roentgenology.

[13]  M. Prokop,et al.  Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2005, Radiology.

[14]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[15]  V. Khatri,et al.  Improved accuracy in differentiating malignant from benign mammographic abnormalities , 2001, Cancer.

[16]  Robert E. Lenkinski,et al.  The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy , 2001, Breast Cancer Research and Treatment.

[17]  C. Stelling.  MR imaging of the breast for cancer evaluation. Current status and future directions. , 1995, Radiologic clinics of North America.

[18]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[19]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.

[20]  C. Kuhl,et al.  MRI of breast tumors , 2000, European Radiology.

[21]  Rankin Sc,et al.  MRI of the breast. , 2000 .

[22]  L. Cozzi,et al.  Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography. , 2003, Radiology.

[23]  C. Colosimo,et al.  Detection of Intracranial Metastases: A Multicenter, Intrapatient Comparison of Gadobenate Dimeglumine-Enhanced MRI with Routinely Used Contrast Agents at Equal Dosage , 2001, Investigative radiology.

[24]  Peter B Barker,et al.  Benign and malignant breast lesions: diagnosis with multiparametric MR imaging. , 2003, Radiology.

[25]  V. Runge,et al.  Contrast Agents for Magnetic Resonance Imaging: Safety Update , 2003, Topics in magnetic resonance imaging : TMRI.

[26]  R. Hendrick,et al.  Imaging of the radiographically dense breast. , 1993, Radiology.

[27]  J F Debatin,et al.  Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. , 1998, The British journal of radiology.

[28]  D B Plewes,et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Lee,et al.  Breast conservation therapy in patients with mammographically undetected breast cancer. , 1992, Radiology.

[30]  E. Morris.  Review of breast MRI: indications and limitations. , 2001, Seminars in roentgenology.

[31]  B. Kruse,et al.  Breast cancer: mammographic and sonographic findings after augmentation mammoplasty. , 1990, Radiology.

[32]  T. Helbich,et al.  Contrast-enhanced magnetic resonance imaging of the breast. , 2000, European journal of radiology.

[33]  Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? , 2004, Radiology.

[34]  R. Gilles,et al.  Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. , 1993, Radiology.

[35]  R. Gilles,et al.  Ductal carcinoma in situ: MR imaging-histopathologic correlation. , 1995, Radiology.

[36]  L. Calabi,et al.  Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. , 1999, Journal of computer assisted tomography.

[37]  S. Higano,et al.  Correlation of lesions in the hippocampal region noted on MR images with clinical features , 1997, European Radiology.

[38]  Elizabeth A Morris,et al.  Breast cancer imaging with MRI. , 2002, Radiologic clinics of North America.

[39]  M. Knopp,et al.  Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2004, Radiology.

[40]  Matthijs Oudkerk,et al.  First experiences in screening women at high risk for breast cancer with MR imaging , 2000, Breast Cancer Research and Treatment.

[41]  E Grabbe,et al.  Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. , 1999, Radiology.

[42]  S. Edge,et al.  Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. , 1995, Radiology.